As IL-1β likely contributes to both IBD and arthritis in these patients, anti-IL-1 therapy may be considered to suppress the inflammatory component of the disease although none of the reported patients received targeted IL-1 inhibitors. The gene discussed is IL1B; the disease is arthritic joint disease.